FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 80462

News■ Unclear/unknown

Saving Heart Muscle After a Heart Attack: Nature Reports PeriFlow's First-in-Class Capillary-Selective Vasodilator

KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A preclinical drug candidate targeting capillary no-reflow is early-stage and not yet investable at scale.

Early-stage cardiovascular drug, long path to market
CATALYST TO WATCH

IND filing or trial initiation

MAIN RISK

Preclinical failure risk is high

FULL DISPATCH

PeriFlow Therapeutics is advancing CLN-2501, a first-in-class drug candidate designed to restore capillary blood flow after Acute Myocardial Infarction by targeting a newly-druggable mechanism of "Capillary No-Reflow." The program is moving toward clinical development in the US. BOSTON,...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-14 17:30 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.